Dezawa Muse cells (Multilineage-differentiating Stress-Enduring cells) are a naturally occurring class of pluripotent stem cells discovered in 2010 by Professor Mari Dezawa at Tohoku University in Japan. They are isolated from adult human tissues such as bone marrow and peripheral blood. In published research, they can differentiate into cells from all three germ layers without genetic modification and without forming tumors in animal models. They are an active area of regenerative medicine research and are not FDA-approved for any indication in the United States.
What does "Muse cell" actually mean?
"Muse" is an acronym for Multilineage-differentiating Stress-Enduring. The name describes two of the most distinctive properties researchers have observed:
- Multilineage-differentiating - the cells can become tissue types from all three germ layers (ectoderm, mesoderm, endoderm), the same broad capacity as embryonic stem cells.
- Stress-Enduring - the cells survive in conditions that kill most other cells, including low oxygen, inflammation, and oxidative stress.
The word "Dezawa" attached to the name acknowledges Professor Mari Dezawa, MD, PhD, the Tohoku University researcher who first isolated and characterized them in 2010.
Where do Dezawa Muse cells come from?
Muse cells occur naturally in adult human tissue. The most common sources used in research and licensed clinical applications include:
- Bone marrow - historically the most studied source.
- Adipose (fat) tissue - accessible and abundant in connective tissue stroma.
- Peripheral blood - circulating Muse cells can be isolated non-invasively.
- Umbilical cord tissue - used by some manufacturers for allogeneic (donor-derived) products.
The catch: Muse cells make up only about 1 to 4 percent of typical mesenchymal stem cell populations. Without specialized isolation, you don't get a Muse cell product - you get a regular MSC product with a small Muse fraction inside it. That's why authentic Dezawa Muse cell therapy uses defined isolation by the SSEA-3 surface marker.
What is SSEA-3 and why does it matter?
SSEA-3 (Stage-Specific Embryonic Antigen 3) is the protein marker on the cell surface that identifies an authentic Muse cell. It is the gold-standard verification used in published Dezawa research.
If a clinic claims to offer "Muse cells" but cannot show SSEA-3+ verification on the batch you'll receive, you have no way to confirm what is actually being administered. Authentic Dezawa Muse cell programs include certificates of analysis with SSEA-3 status as part of standard quality control.
How are Muse cells different from other stem cells?
Most stem cell therapies fall into one of three categories. Here is how Dezawa Muse cells compare:
Mesenchymal stem cells (MSCs)
The most widely used adult stem cell. Multipotent - meaning they differentiate into a limited range of mesodermal tissue (bone, cartilage, fat, muscle). Substantial clinical trial data exists for MSC infusion in cardiovascular disease, autoimmune conditions, and orthopedics. MSCs are safe but have limited capacity to become tissue outside the mesoderm.
Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)
Truly pluripotent - they can become any tissue type. The catch: in published animal studies, both can form teratomas (a type of tumor) when injected as undifferentiated cells. iPSCs additionally require genetic modification to be created. These limitations have constrained their clinical use.
Dezawa Muse cells
Pluripotent like ESCs and iPSCs, but with a different gene expression profile (notably elevated Let-7 and reduced Lin28) that researchers describe as a built-in tumor-suppression signature. Published preclinical safety studies have not observed teratoma formation. They also do not require genetic modification - they exist naturally in adult tissue. Read the full comparison →
How were Dezawa Muse cells discovered?
The discovery was published in 2010 in the Proceedings of the National Academy of Sciences by Professor Mari Dezawa and colleagues at Tohoku University. The team was studying mesenchymal stem cell populations under stress conditions and noticed a small subset of cells that survived hostile environments where the rest died.
Further characterization revealed these surviving cells expressed pluripotency markers (Nanog, Oct3/4, Sox2, SSEA-3) yet lacked the gene expression signature associated with tumor formation in embryonic stem cells. That combination - pluripotency without tumorigenicity - was the breakthrough. Read the full discovery story →
What can Dezawa Muse cells potentially do?
Researchers have studied four distinct biological behaviors that distinguish Muse cells from typical stem cell populations:
- Active migration to injury sites. Muse cells express the S1P-S1PR2 receptor system, which appears to direct them toward damaged tissue rather than getting trapped in lung capillaries (a known limitation of IV-administered MSCs).
- Spontaneous differentiation through phagocytosis. When Muse cells reach an injury site and engulf apoptotic (dying) cells, they appear to differentiate into the same tissue type that was lost - without needing an external signal.
- Immune privilege. Muse cells express HLA-G, IDO, and lack HLA-DR - a profile associated with immune tolerance. In published clinical use, immunosuppressive drugs have not been required.
- Stress endurance. Their hallmark survival capacity in hypoxia, inflammation, and oxidative stress means they can theoretically function inside the very environments where most other cells fail - exactly where regeneration is needed.
For the full mechanism of action, see How Do Dezawa Muse Cells Work?
What conditions are Dezawa Muse cells being studied for?
Active research and Phase I/II clinical trials in Japan have evaluated Dezawa Muse cells across several indications:
- Acute myocardial infarction (heart attack) - the largest published clinical trial dataset.
- Stroke recovery and ischemic brain injury.
- Spinal cord injury.
- Epidermolysis bullosa (a genetic skin disorder).
- Acute respiratory distress syndrome (ARDS).
None of these uses are FDA-approved in the United States, and individual outcomes vary. Read the full list of conditions and trial identifiers →
Are Dezawa Muse cells safe?
Published preclinical and Phase I/II clinical data report a favorable safety profile, with no reports of teratoma formation in long-term animal studies and no requirement for immunosuppressive medication. Stable karyotype has been documented across extended cell culture, and the gene expression pattern (Let-7 elevated, Lin28 suppressed) is associated with tumor suppression in published research.
That said, "safer than alternatives in published studies" is not the same as "FDA approved" or "guaranteed safe for any patient." A complete safety conversation requires a physician review of your individual health history. Read the full safety review →
Key citations and sources
- Kuroda Y, Kitada M, Wakao S, et al. (2010). Unique multipotent cells in adult human mesenchymal cell populations. Proceedings of the National Academy of Sciences, 107(19):8639-8643.
- Wakao S, Kuroda Y, Ogura F, Shigemoto T, Dezawa M. (2012). Regenerative effects of Mesenchymal Stem Cells: Contribution of Muse cells, a novel pluripotent stem cell type. Cells, 1(4):1045-1060.
- Phase II clinical trial program, Life Science Institute (LSI), subsidiary of Mitsubishi Chemical Group, Japan.
- ClinicalTrials.gov registry - search "Muse cells" for active and completed studies.
Frequently asked questions
What does "Dezawa Muse cell" mean?
"Dezawa" credits Professor Mari Dezawa, the Tohoku University researcher who discovered them in 2010. "Muse" stands for Multilineage-differentiating Stress-Enduring - the two properties that distinguish them from other stem cells.
Are Muse cells the same as stem cells?
Muse cells are a specific subtype of pluripotent stem cell isolated from adult tissue. They share some properties with mesenchymal stem cells (their tissue source) and with embryonic stem cells (their pluripotency), but they are not identical to either. The defining feature is the SSEA-3+ surface marker.
How rare are Muse cells?
Muse cells make up roughly 1 to 4 percent of typical mesenchymal stem cell populations in adult tissue. That rarity is why specialized SSEA-3-based isolation is required to produce a defined Muse cell product.
Can Muse cells form tumors?
In published preclinical studies, including long-term implantation in immunodeficient mouse models, Dezawa Muse cells have not been observed to form teratomas (the tumor type associated with embryonic stem cells and iPSCs). Their gene expression profile, with elevated Let-7 and suppressed Lin28, is associated with active tumor suppression in published research.
How are Dezawa Muse cells administered?
In published clinical trials, intravenous (IV) infusion has been the primary route. The S1P-S1PR2 homing system is theorized to direct cells from circulation to injury sites. Other routes are under investigation.
Are Dezawa Muse cells available in the United States?
Dezawa Muse cells are an active area of regenerative medicine research and have not received FDA approval for any indication in the U.S. Some U.S. physicians offer regenerative medicine programs that involve cell-based products under specific regulatory frameworks. Patient eligibility is determined on an individual basis after clinical evaluation.
Have a question about regenerative medicine?
Dr. Capasso offers a complimentary 45-minute consultation to review your health history, answer your questions, and provide an clear assessment of whether regenerative therapies are appropriate for your situation.
Book a Consultation